Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy

Clin Cancer Res. 2021 Jan 15;27(2):374-376. doi: 10.1158/1078-0432.CCR-20-3507. Epub 2020 Nov 13.

Abstract

It has been reported that a group of patients with advanced non-small cell lung cancer showed circulating T cells with a senescent phenotype, and an abundance of such cells is associated with worse clinical response to immune checkpoint inhibitors. This study encourages further analysis of the role of senescent T cells in resistance to lung cancer immunotherapy.See related article by Ferrara et al., p. 492.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunosenescence*
  • Immunotherapy
  • Lung Neoplasms* / drug therapy
  • Platinum / therapeutic use
  • Programmed Cell Death 1 Receptor / therapeutic use
  • T-Lymphocytes

Substances

  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor
  • Platinum